a Laboratory of Molecular Medicine , Institute of Chemical Biology and Fundamental Medicine of SB RAS , Novosibirsk , Russia.
b Laboratory of Biomedical Technologies, Centre of New Surgical Technologies , E.N. Meshalkin Siberian Federal Biomedical Research Center , Novosibirsk , Russia.
Expert Rev Mol Diagn. 2018 Feb;18(2):133-145. doi: 10.1080/14737159.2018.1425143. Epub 2018 Jan 15.
Cancer statistics show that recent improvements in cancer management are only mildly effective in the absence of reliable biomarkers for the detection, diagnosis and monitoring of malignant disease. Recently circulating nucleic acids have been suggested as potential biomarker candidates to fill this role. Areas covered: This review focuses on the different types of circulating RNA biomarkers under investigation, describing the latest advances in their development and application to clinical settings, as well as challenges that researchers face in the process. Immediate perspectives of the field are outlined, and authors' recommendations on the best progression path are provided. Expert commentary: The development of RNA-based cancer biomarkers is a thriving area of biomedical research that has progressed significantly over the last decade. However, it seems that it is now at the point, where unless several key issues are resolved, no significant progress can be made further. Currently several areas of biomarker research require re-assessment, as indicated by the latest findings regarding the biology of circulating nucleic acids and the accumulated data of their analysis using various techniques. Additionally, regulating agencies need to be working alongside researchers to facilitate faster and easier adoption of new effective biomarkers into the clinical practice.
癌症统计数据表明，在缺乏可靠的生物标志物用于恶性疾病的检测、诊断和监测的情况下，最近癌症治疗的进展仅略有成效。最近，循环核酸被认为是填补这一空白的潜在生物标志物候选物。
本综述重点介绍了正在研究的不同类型的循环 RNA 生物标志物，描述了它们在开发和应用于临床环境方面的最新进展，以及研究人员在这一过程中面临的挑战。概述了该领域的即时展望，并提供了作者对最佳进展路径的建议。
基于 RNA 的癌症生物标志物的开发是生物医学研究中一个蓬勃发展的领域，在过去十年中取得了重大进展。然而，现在似乎除非解决几个关键问题，否则无法取得进一步的重大进展。目前，一些生物标志物研究领域需要重新评估，这是由最近关于循环核酸生物学的发现以及使用各种技术对其分析所积累的数据所表明的。此外，监管机构需要与研究人员合作，以促进将新的有效生物标志物更快、更轻松地纳入临床实践。
